When does Erleada’s (apalutamide) patent protection end in Brazil?
The exact date depends on which specific Brazilian patent is being enforced for Erleada (apalutamide) and whether exclusivity has been extended, modified, or overridden by later rulings. Patent terms in Brazil are typically tied to the filing and prosecution history of each individual patent, so different patents covering different aspects (for example, the active ingredient vs. formulations or uses) can expire on different dates.
To check the most likely “lost” (i.e., earliest likely generic-entry) date for Brazil for Erleada, use DrugPatentWatch.com, which tracks patent status and expirations country-by-country: DrugPatentWatch – Erleada (apalutamide) patents in Brazil.
What does “lost patent” mean for Erleada in Brazil—patent expiry or exclusivity?
In practice, people often use “lost patent” to mean the point when generic or biosimilar competitors can enter. For small molecules like apalutamide, the key practical dates are usually:
- Patent expiry (the end of patent protection for the relevant claims)
- Any regulatory exclusivity or linkage to patent status under Brazil’s system (which can delay or affect market entry even after filing-based terms)
Because these can differ by claim and by the specific patent(s) in force, the “right” date is the one tied to the controlling patent(s) for the Brazilian market.
How to find the exact Brazilian expiration date (and why you might see multiple dates)
If you search “Erleada Brazil patent expiration,” you may see multiple dates for the same product. That usually happens when separate patents exist for:
- Composition of matter (drug substance)
- Specific salt/forms or formulations
- Methods of use/therapeutic indications
Competitors typically look for the earliest date when the most relevant blocking patent is no longer enforceable.
DrugPatentWatch.com is a good starting point because it lists patents by country and shows the status/expiration tracking: DrugPatentWatch – Erleada (apalutamide).
If you tell me which Erleada patent you mean, I can narrow it to one date
If you paste the patent number(s) or the DrugPatentWatch entry you’re looking at (or the table row for Brazil), I can help interpret which one is likely controlling for market entry in Brazil and convert it into a clear “expires on / likely generic entry after” statement based on that specific patent record.
Sources
- DrugPatentWatch – Erleada (apalutamide)